Oof, the lawyers are circling. 🚨 Instil just scrapped its lead drug, and the chart shows why: price is stuck under both key moving averages, and the RSI has been stuck in the "oversold" basement for weeks. This isn't a dip, it's a collapse. The volume spikes are panic, not opportunity. Until the legal dust settles and they find a new direction, this is a clear SELL. #TroubleInTheLab

Instil Bio (TIL) is a rollercoaster! 🎢 After a wild 641% surge, the stock nosedived on 4/25 with a close at $12.78 (from $19.61). The 9-day EMA crossed below the 21-day, signaling bearish momentum. RSI dropped from overbought (79) to neutral (46), suggesting cooling off. Volume spiked on the sell-off—not a great sign. News is mixed: clinical progress vs. volatility. If you’re holding, watch for support near $12. New buyers? Wait for stabilization. High-risk, high-reward play! 🚀⚠️

This stock is a coiled spring! 📈 Oversold RSI and bullish intraday reversal are screaming "bounce." The news? A firehose of catalysts: IND clearances, key data due, and a 300% upside target from Jefferies. The chart shows buyers are finally stepping in. This isn't a drill. BUY. #BiotechRocket

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Instil Bio, Inc. TIL: 8.48 USD

Bullish views

Bearish views